Latest Pharma and Biotech News
Biotechnology
3 December 2024 US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.
Today's issue
Refine Search
Pharmaceutical
AstraZeneca has brought in Iskra Reic to replace Leon Wang, who is on extended leave from the Anglo-Swedish drugmaker while under investigation in China. 4 December 2024
Biotechnology
Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules targeting RNA for oncology and neurological disorders, announced today that it has entered into a multi-year, multi-target strategic research alliance with the UK’s GSK. 4 December 2024
Biotechnology
Shares of US precision medicines firm Relay Therapeutics closed down 6% at $4.39 yesterday after announced a licensing deal for its lirafugratinib. 4 December 2024
Biotechnology
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, has entered into a strategic research collaboration with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC). 4 December 2024
Biotechnology
Chinese biotech Duality Biologics yesterday revealed that it has entered into an exclusive option agreement with UK pharma major GSK for a potentially best-in-class ADC candidate, DB-1324. 4 December 2024
Biotechnology
Cartesian Therapeutics announced updated results from a Phase IIb trial of Descartes-08 for generalized myasthenia gravis. 4 December 2024
Biosimilars
Accord BioPharma, a specialty division of Intas Pharmaceuticals, has entered into an agreement to acquire Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv) business. 4 December 2024
Pharmaceutical
The battle between the two front runners in the vast weight loss treatment market took a turn today, when US pharma major Eli Lilly released top-line results from the SURMOUNT-5 Phase IIIb open-label randomized clinical trial. 4 December 2024
Biotechnology
Boston-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has entered a research collaboration and option agreement with US pharma major Bristol Myers Squibb. 4 December 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is being urged to rebuild its reputation following an internal restructuring, as the regulator finds its feet in a post-Brexit environment. 4 December 2024
Pharmaceutical
Spanish drugmaker PharmaMar Group revealed that its licensing partner, Luye Pharma Group, has received conditional marketing approval for Zepzelca (lurbinectedin) from the China National Medical Products Administration (NMPA). 4 December 2024
Biotechnology
Refoxy Pharmaceuticals has raised 9.1 million euros ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. 4 December 2024
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration agreement with privately-held Canadian firm Congruence Therapeutics. 4 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Anzupgo (delgocitinib) cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate, from Danish dermatology specialist LEO Pharma. 4 December 2024
Pharmaceutical
Danish drug developer Antag Therapeutics, which is pioneering novel treatments for obesity, today announced the closing of an 80 million euros ($83.8 million) Series A financing. 4 December 2024
Pharmaceutical
Maze Therapeutics, a California-based biotech, has raised $115 million in a series D financing round co-led by Frazier Life Sciences and Deep Track Capital. 4 December 2024
Biotechnology
Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. 3 December 2024
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Pharmaceutical
US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche subsidiary Genentech for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. 3 December 2024
All news
Pharmaceutical
AstraZeneca has brought in Iskra Reic to replace Leon Wang, who is on extended leave from the Anglo-Swedish drugmaker while under investigation in China. 4 December 2024
Biotechnology
Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules targeting RNA for oncology and neurological disorders, announced today that it has entered into a multi-year, multi-target strategic research alliance with the UK’s GSK. 4 December 2024
Biotechnology
Shares of US precision medicines firm Relay Therapeutics closed down 6% at $4.39 yesterday after announced a licensing deal for its lirafugratinib. 4 December 2024
Biotechnology
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, has entered into a strategic research collaboration with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC). 4 December 2024
Biotechnology
Chinese biotech Duality Biologics yesterday revealed that it has entered into an exclusive option agreement with UK pharma major GSK for a potentially best-in-class ADC candidate, DB-1324. 4 December 2024
Biotechnology
Cartesian Therapeutics announced updated results from a Phase IIb trial of Descartes-08 for generalized myasthenia gravis. 4 December 2024
Biosimilars
Accord BioPharma, a specialty division of Intas Pharmaceuticals, has entered into an agreement to acquire Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv) business. 4 December 2024
Pharmaceutical
The battle between the two front runners in the vast weight loss treatment market took a turn today, when US pharma major Eli Lilly released top-line results from the SURMOUNT-5 Phase IIIb open-label randomized clinical trial. 4 December 2024
Biotechnology
Boston-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has entered a research collaboration and option agreement with US pharma major Bristol Myers Squibb. 4 December 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is being urged to rebuild its reputation following an internal restructuring, as the regulator finds its feet in a post-Brexit environment. 4 December 2024
Pharmaceutical
Spanish drugmaker PharmaMar Group revealed that its licensing partner, Luye Pharma Group, has received conditional marketing approval for Zepzelca (lurbinectedin) from the China National Medical Products Administration (NMPA). 4 December 2024
Biotechnology
Refoxy Pharmaceuticals has raised 9.1 million euros ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. 4 December 2024
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration agreement with privately-held Canadian firm Congruence Therapeutics. 4 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Anzupgo (delgocitinib) cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate, from Danish dermatology specialist LEO Pharma. 4 December 2024
Pharmaceutical
Danish drug developer Antag Therapeutics, which is pioneering novel treatments for obesity, today announced the closing of an 80 million euros ($83.8 million) Series A financing. 4 December 2024
Pharmaceutical
Maze Therapeutics, a California-based biotech, has raised $115 million in a series D financing round co-led by Frazier Life Sciences and Deep Track Capital. 4 December 2024
Biotechnology
Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. 3 December 2024
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Pharmaceutical
US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche subsidiary Genentech for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. 3 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze